{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:04:43Z","timestamp":1768467883583,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"HSRI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijid.2022.07.040","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T06:15:05Z","timestamp":1658211305000},"page":"725-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection"],"prefix":"10.1016","volume":"122","author":[{"given":"Weeraya","family":"Phaisal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-3499","authenticated-orcid":false,"given":"Watsamon","family":"Jantarabenjakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1499-6940","authenticated-orcid":false,"given":"Noppadol","family":"Wacharachaisurapol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7776-2781","authenticated-orcid":false,"given":"Monta","family":"Tawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1873-1867","authenticated-orcid":false,"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supeecha","family":"Wittayalertpanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-6020","authenticated-orcid":false,"given":"Pajaree","family":"Chariyavilaskul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.07.040_bib0001","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003088-198814060-00002","article-title":"Influences of diet and nutrition on clinical pharmacokinetics","volume":"14","author":"Anderson","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.07.040_bib0002","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM198509263131302","article-title":"The effect of dietary protein on the clearance of allopurinol and oxypurinol","volume":"313","author":"Berlinger","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.07.040_bib0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.inf.0000214963.55217.9c","article-title":"Pharmacokinetics of rifapentine in children","volume":"25","author":"Blake","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2022.07.040_bib0004","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2022.07.040_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186200","article-title":"Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2022.07.040_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01381-20","article-title":"Population pharmacokinetics of cycloserine and pharmacokinetic\/pharmacodynamic target attainment in multidrug-resistant tuberculosis patients dosed with terizidone","volume":"64","author":"Chirehwa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0007","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tube.2007.05.012","article-title":"Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis","volume":"87","author":"Cho","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijid.2022.07.040_bib0008","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.5588\/ijtld.18.0775","article-title":"Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis","volume":"23","author":"Court","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0009","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/INF.0000000000001164","article-title":"Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatrictuberculosisinfection","volume":"35","author":"Cruz","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2022.07.040_bib0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-2838","article-title":"Completion rate and safety of tuberculosis infection treatment with shorter regimens","volume":"141","author":"Cruz","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2022.07.040_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2022.07.040_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-18","article-title":"A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine","volume":"63","author":"Francis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0013","first-page":"398","article-title":"Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products","volume":"9","author":"Glass","year":"2006","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.ijid.2022.07.040_bib0014","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.5588\/ijtld.18.0168","article-title":"Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review","volume":"22","author":"Hamada","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17476348.2020.1694907","article-title":"Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up","volume":"14","author":"Harries","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ijid.2022.07.040_bib0016","first-page":"231","article-title":"A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine","volume":"36","author":"Hemanth Kumar","year":"2004","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0017","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.07.040_bib0018","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.3748\/wjg.v13.45.6003","article-title":"NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis","volume":"13","author":"Higuchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0019","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2022.07.040_bib0020","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.43.5.1230","article-title":"Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study","volume":"43","author":"Keung","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/FPC.0000000000000232","article-title":"PharmGKB summary: isoniazid pathway, pharmacokinetics","volume":"26","author":"Klein","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ijid.2022.07.040_bib0022","first-page":"530","article-title":"Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs","volume":"145","author":"Kumar","year":"2017","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijid.2022.07.040_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jfma.2014.01.015","article-title":"Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients","volume":"113","author":"Lin","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ijid.2022.07.040_bib0024","unstructured":"Ministry of Public Health. Health-KPI. http:\/\/healthkpi.moph.go.th\/kpi\/kpi_template\/2563\/025.1.pdf, 2020 (accessed 11 April 2020)."},{"key":"10.1016\/j.ijid.2022.07.040_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HMER.S290542","article-title":"Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia","volume":"13","author":"Molla","year":"2021","journal-title":"Hepat Med"},{"key":"10.1016\/j.ijid.2022.07.040_bib0026","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17425255.2018.1416093","article-title":"Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?","volume":"14","author":"Motta","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0027","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1086\/508278","article-title":"Rifapentine for the treatment of pulmonary tuberculosis","volume":"43","author":"Munsiff","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0028","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0029","unstructured":"National Institute of Allergy and Infectious Diseases. DAIDS adverse event grading tables. https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables, 2017 (accessed 10 May 2019)."},{"key":"10.1016\/j.ijid.2022.07.040_bib0030","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-054663","article-title":"Tuberculosis infection in children and adolescents: testing and treatment","volume":"148","author":"Nolt","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2022.07.040_bib0031","first-page":"256","article-title":"Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity","volume":"4","author":"Ohno","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1039\/C7AY02686B","article-title":"Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed-dose combination antituberculosis pharmaceutical formulations: a review","volume":"10","author":"Oliveira","year":"2018","journal-title":"Anal Methods"},{"key":"10.1016\/j.ijid.2022.07.040_bib0033","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00003088-198917060-00006","article-title":"Effect of dietary protein on renal tubular clearance of drugs in humans","volume":"17","author":"Park","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.07.040_bib0034","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/ppul.25456","article-title":"Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: a chart and literature review","volume":"56","author":"Peck","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00228-008-0484-8","article-title":"Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil","volume":"64","author":"Possuelo","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0036","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jpba.2006.03.004","article-title":"Study of the interaction between rifapentine and isoniazid under acid conditions","volume":"41","author":"Prasad","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijid.2022.07.040_bib0037","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkv394","article-title":"Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial","volume":"71","author":"Saktiawati","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0038","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0039","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure\u2013response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2022.07.040_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0041-3879(62)80046-4","article-title":"Studies on the inactivation of isonicotinyl acid hydrazide in normal subjects and tuberculous patients","volume":"43","author":"Short","year":"1962","journal-title":"Tubercle"},{"key":"10.1016\/j.ijid.2022.07.040_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ijid.2022.07.040_bib0042","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicenter randomized controlled trial in Taiwan","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijid.2022.07.040_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02692-18","article-title":"Genomewide association study confirming the association of NAT2 with susceptibility to antituberculosis drug-induced liver injury in Thai patients","volume":"63","author":"Suvichapanich","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0044","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1086\/431984","article-title":"Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana","volume":"41","author":"Tappero","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0046","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ijid.2022.07.040_bib0047","doi-asserted-by":"crossref","first-page":"e22258","DOI":"10.1097\/MD.0000000000022258","article-title":"Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.ijid.2022.07.040_bib0048","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5588\/ijtld.15.0310","article-title":"NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients","volume":"20","author":"Wattanapokayakit","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2022.07.040_bib0049","first-page":"177","article-title":"Biostatistics: a foundation for analysis in the health sciences","volume":"37","author":"Wayne","year":"1995","journal-title":"Biom J"},{"key":"10.1016\/j.ijid.2022.07.040_bib0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003088-197904060-00001","article-title":"Clinical pharmacokinetics of isoniazid","volume":"4","author":"Weber","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.07.040_bib0051","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkaa490","article-title":"Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis","volume":"76","author":"Weiner","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0052","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jpids\/pit077","article-title":"Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection","volume":"3","author":"Weiner","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.ijid.2022.07.040_bib0053","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2022.07.040_bib0054","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.07.040_bib0055","unstructured":"World Health Organization. Country profiles for 30 high TB burden countries. Annex 2. https:\/\/www.who.int\/tb\/publications\/global_report\/tb19_Report_country_profiles_15October2019.pdf, 2019 (accessed 8 April 2020)."},{"key":"10.1016\/j.ijid.2022.07.040_bib0056","unstructured":"World Health Organization. Tuberculosis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis, 2020 (accessed 10 May 2020)."},{"key":"10.1016\/j.ijid.2022.07.040_bib0057","unstructured":"World Health Organization. WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. https:\/\/www.who.int\/news\/item\/17-06-2021-who-releases-new-global-lists-of-high-burden-countries-for-tb-hiv-associated-tb-and-drug-resistant-tb, 2021 (accessed 6 July 2021)."},{"key":"10.1016\/j.ijid.2022.07.040_bib0058","article-title":"High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-a single center study","volume":"16","author":"Yang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2022.07.040_bib0059","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12248-021-00570-4","article-title":"Assessing food effects on oral drug absorption based on the degree of renal excretion","volume":"23","author":"Zhang","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.ijid.2022.07.040_bib0060","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222004349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222004349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T14:36:09Z","timestamp":1715438169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222004349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":60,"alternative-id":["S1201971222004349"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.07.040","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}